Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension
- 21 April 2023
- journal article
- review article
- Published by Springer Nature in Herz
- Vol. 48 (4) , 259-265
Abstract
The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for pulmonary hypertension have introduced a refined risk stratification to guide both initial and subsequent treatment of pulmonary arterial hypertension (PAH). The risk stratification at PAH diagnosis still comprises three risk categories (low, intermediate, high) and lists some new parameters. As the estimated 1‑year mortality is more than 20% in high-risk patients after diagnosis, an initial triple-combination therapy including parenteral prostacyclin analogues is recommended for this group. All other patients should receive a dual-combination therapy with an endothelin receptor antagonist and a phosphodiesterase‑5 inhibitor. However, this approach of initial combination therapy is only recommended for classic PAH, while monotherapy followed by regular follow-up and individualized therapy should be used for patients with cardiopulmonary comorbidities. For PAH patients without cardiopulmonary comorbidities, it is recommended to assess their risk at follow-up with a new 4‑strata classification, where the intermediate-risk group is split on the basis of three noninvasive parameters. Importantly, changes from intermediate–high to intermediate–low risk have been shown to be associated with a better prognosis. In addition, the recommendations on treatment escalation became more precise with the addition of a prostacyclin receptor agonist or switching a phosphodiesterase‑5 inhibitor to a soluble guanylate cyclase stimulator for intermediate–low risk and proceeding to triple-combination therapy with parenteral prostacyclin analogues already for intermediate–high risk. With sotatercept, the first non-vasodilator PAH treatment will become available in the near future to further enrich our treatment options for this chronic and still severe disease.Keywords
This publication has 41 references indexed in Scilit:
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial HypertensionRespiration, 2015
- Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller HypertonieDMW - Deutsche Medizinische Wochenschrift, 2014
- Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL RegistryThe Journal of Heart and Lung Transplantation, 2013
- Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial HypertensionCirculation, 2013
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Long-term outcome with intravenous iloprost in pulmonary arterial hypertensionEuropean Respiratory Journal, 2009
- Goal-oriented treatment and combination therapy for pulmonary arterial hypertensionEuropean Respiratory Journal, 2005